Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OMD Appoints RGi for the Industrial Design of Breath Ketone Analysis Platform

Published: Tuesday, March 25, 2014
Last Updated: Tuesday, March 25, 2014
Bookmark and Share
New system aims to reduce the incidence of Diabetic KetoAcidosis.

Oxford Medical Diagnostics (OMD) has contracted Renfrew Group International (RGi) for the industrial design of a portable breath analysis platform based upon OMD’s prototype device.

The collaboration will combine OMD’s scientific research expertise with RGi’s design capabilities to further develop an accurate, low-cost, portable and non-invasive breath analysis platform to identify and monitor certain metabolic and infectious diseases by detecting and measuring VOCs in breath.

The current device is designed for use in Type 1 diabetes, as an aid to diabetes management and to help prevent the onset of Diabetic KetoAcidosis (DKA).

In recent months the prototype system was successfully used in its first clinical evaluation, successfully measuring breath acetone from over 100 samples.

OMD’s platform is based on the Company’s main proprietary technology, Cavity Enhanced Absorption Spectroscopy (CEAS), which was developed at the University of Oxford.

The current prototype device is capable of measuring acetone in breath samples at sub-parts-per-million levels, which is in excess of the sensitivity required to detect acetone levels of patients with Type 1 diabetes.

OMD has been awarded SBRI funding and two TSB grants to support this work. The Company is currently performing the next phase of clinical trials in collaboration with an expert team at Addenbrookes Hospital in Cambridge under the direction of Dr Mark Evans.

OMD's CEO, Dr Ian Campbell, stated: "Appointing RGi is a significant step forward for OMD. Given the robust performance of the prototype in the clinical evaluation we are now in a position to move forward with a design for manufacture.”

Bruce Renfrew, Managing Director of RGi commented: “RGi is delighted to be working with OMD to industrialize this innovative, non-invasive diagnostic platform.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oxford Medical Diagnostics and Michell Instruments Launch Gas Analysis Partnership
OMD and MI will jointly develop new industrial gas detection and measurement devices for a number of industrial applications.
Wednesday, August 17, 2011
OMD Obtains Close to GBP One Million in New Financing Round
Current investors and shareholders provide funding for further development of breath analysis device for diabetes.
Friday, June 03, 2011
OMD and V&F Join Forces in the Field of Mass Spectrometry
Oxford Medical Diagnostics will offer V&F mass spectrometry analyzers and batch sample analysis service in the UK and Ireland.
Tuesday, March 08, 2011
Graham Richards joins Science Advisory Panel at Oxford Medical Diagnostics
Entrepreneurial Oxford professor will also bring his experience of successful technology start-ups to breath analysis specialists.
Monday, January 24, 2011
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!